

# Treatment Resistant Depression - Pipeline Insight, 2021

<https://marketpublishers.com/r/T27B8F3C686EN.html>

Date: July 2021

Pages: 60

Price: US\$ 2,000.00 (Single User License)

ID: T27B8F3C686EN

## Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Treatment Resistant Depression - Pipeline Insight, 2021," report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Treatment Resistant Depression pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### Treatment Resistant Depression Understanding

#### Treatment Resistant Depression: Overview

The term "treatment resistant depression" often refers to major depressive episodes that do not respond satisfactorily to at least two trials of antidepressant monotherapy; however, the definition has not been standardized. Pharmacologic treatment options comprise switching, combination, and potentiation strategy among the commonly used antidepressant drugs. The majority of the available antidepressants such as Selective Serotonin Reuptake Inhibitor (SSRI), Dual serotonin and norepinephrine reuptake inhibitors (SNRIs), Tricyclic antidepressant, Irreversible, non-selective monoamine oxidase inhibitors (MAOIs),  $\alpha$ -2-antagonists, Agomelatine, Tianeptine are used for

Treatment-Resistant Depression Treatment. Switching is recommended when there is no response or low tolerance to the initial treatment, inadequate response to the newly introduced treatment. Selective Serotonin Reuptake Inhibitor (SSRI) is considered a first-line treatment, nevertheless of the clinical severity. When there is no response from SSRI, norepinephrine reuptake inhibitors (SNRIs) are taken into consideration. But, there is no response from SNRIs; the next approach is a tricyclic antidepressant.

'Treatment Resistant Depression - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Treatment Resistant Depression pipeline landscape is provided which includes the disease overview and Treatment Resistant Depression treatment guidelines. The assessment part of the report embraces, in depth Treatment Resistant Depression commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Treatment Resistant Depression collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Treatment Resistant Depression R&D. The therapies under development are focused on novel approaches to treat/improve Treatment Resistant Depression.

## Treatment Resistant Depression Emerging Drugs Chapters

This segment of the Treatment Resistant Depression report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## Treatment Resistant Depression Emerging Drugs

### Psilocybin: COMPASS Pathways

Psilocybin therapy is an approach being investigated for the treatment of mental health challenges. It combines the pharmacological effects of psilocybin, a psychoactive substance, with psychological support. Psilocybin is an active ingredient in some species of mushrooms, often referred to as 'magic mushrooms'. The company has developed a synthesised formulation of psilocybin, COMP 360, and is investigating the effectiveness of psilocybin therapy, initially in treatment-resistant depression.

#### AXS-05: Axsome Therapeutics

AXS-05 is a novel, oral, investigational NMDA receptor antagonist with multimodal activity being developed for the treatment of central nervous system (CNS) conditions. AXS-05 consists of a proprietary formulation and dose of dextromethorphan (DM) and bupropion. The dextromethorphan component of AXS-05 is an antagonist of the NMDA receptor, an ionotropic glutamate receptor, and a sigma-1 receptor agonist. These actions modulate glutamatergic neurotransmission. The bupropion component of AXS-05 serves primarily to increase the bioavailability of dextromethorphan, and is a norepinephrine and dopamine reuptake inhibitor

Further product details are provided in the report.....

#### Treatment Resistant Depression: Therapeutic Assessment

This segment of the report provides insights about the different Treatment Resistant Depression drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in Treatment Resistant Depression

There are approx. 25+ key companies which are developing the therapies for Treatment Resistant Depression. The companies which have their Treatment Resistant Depression drug candidates in the most advanced stage, i.e. preregistration include, Axsome Therapeutics.

#### Phases

DelveInsight's report covers around 25+ products under different phases of clinical development like

Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Treatment Resistant Depression pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Treatment Resistant Depression: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Treatment Resistant Depression therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Treatment Resistant Depression drugs.

Treatment Resistant Depression Report Insights

Treatment Resistant Depression Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Treatment Resistant Depression Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

## Key Questions

### Current Treatment Scenario and Emerging Therapies:

How many companies are developing Treatment Resistant Depression drugs?

How many Treatment Resistant Depression drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Treatment Resistant Depression?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Treatment Resistant Depression therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Treatment Resistant Depression and their status?

What are the key designations that have been granted to the emerging drugs?

## Key Players

Axsome Therapeutics

COMPASS Pathways

Merck Sharp & Dohme Corp.

Navitor Pharmaceuticals, Inc.

Taisho Pharmaceutical Co., Ltd.

GH Research Limited

Novartis Pharmaceuticals

Reckitt Benckiser LLC

Relmada Therapeutics, Inc.

SAGE Therapeutics

Navitor Pharmaceuticals

Sumitomo Dainippon Pharma

Alkermes

AbbVie

Janssen Pharmaceuticals

Celon Pharma

ACADIA Pharmaceuticals

Pherin Pharmaceuticals

ATAI Life Sciences

## Key Products

Psilocybin

AXS-05

MK-1942

NV-5138

TS-161

GH 001

MIJ821

venlafaxine XR

REL-1017

SAGE-217

NV-5138

SEP-378614

ALKS-5461

Cariprazine

Seltorexant

Esketamine DPI

Pimavanserin

PH 10 nasal spray

Arketamine



## Contents

Introduction

Executive Summary

Treatment Resistant Depression: Overview

Causes

Mechanism of Action

Signs and Symptoms

Diagnosis

Disease Management

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Late Stage Products (Preregistration)

Comparative Analysis

AXS-05: Axsome Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

Psilocybin: COMPASS Pathways

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

Comparative Analysis

SEP-378614: Sumitomo Dainippon Pharma

Product Description

Research and Development

Product Development Activities  
Drug profiles in the detailed report.....  
Preclinical and Discovery Stage Products  
Comparative Analysis  
Drug name: Company name  
Product Description  
Research and Development  
Product Development Activities  
Drug profiles in the detailed report.....

Inactive Products  
Comparative Analysis  
Treatment Resistant Depression Key Companies  
Treatment Resistant Depression Key Products  
Treatment Resistant Depression- Unmet Needs  
Treatment Resistant Depression- Market Drivers and Barriers  
Treatment Resistant Depression- Future Perspectives and Conclusion  
Treatment Resistant Depression Analyst Views  
Treatment Resistant Depression Key Companies  
Appendix

## List Of Tables

### LIST OF TABLES

Table 1 Total Products for Treatment Resistant Depression

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

Figure 1 Total Products for Treatment Resistant Depression

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

## I would like to order

Product name: Treatment Resistant Depression - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/T27B8F3C686EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/T27B8F3C686EN.html>